A short half-life of the administered factor XIII (FXIII) concentrates after the first replacement therapy in a newborn with severe congenital FXIII deficiency

被引：2
|
作者：
Fujii, Noriko [2 ]
Souri, Masayoshi [1 ]
Ichinose, Akitada [1 ]
机构：
[1] Yamagata Univ, Sch Med, Dept Mol Pathobiochem & Pathobiol, Yamagata 9909585, Japan
[2] Fukuchiyama City Hosp, Dept Pediat, Fukuchiyama, Japan
来源：
THROMBOSIS AND HAEMOSTASIS | 2012年 / 107卷 / 03期
关键词：
PHARMACOKINETICS;
D O I：
10.1160/TH11-09-0625
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：592 / 594
页数：3
相关论文
共 7 条
  • [1] Markedly shortened half-life of the administered factor XIII (FXIII) concentrates during first replacement therapy in a newborn with severe congenital FXIII deficiency
    Fujii, N.
    Souri, M.
    Shima, M.
    Tomoyasu, C.
    Isoda, K.
    Ichinose, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 373 - 373
  • [2] Successful long-term replacement therapy with FXIII concentrate (Fibrogammin® P) for severe congenital factor XIII deficiency: a prospective multicentre study
    Dreyfus, M.
    Barrois, D.
    Borg, J-Y
    Claeyssens, S.
    Torchet, M-F
    Arnuti, B.
    Pautard, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (06) : 1264 - 1266
  • [3] Discrepancy between activity and antigen levels of factor (F) XIII after administration of FXIII concentrates in hemorrhagic acquired FXIII deficiency due to its autoantibody
    Ishida, F.
    Okubo, K.
    Ito, T.
    Okumura, N.
    Souri, M.
    Ichinose, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 122 - 122
  • [4] PLATELET AND PLASMA FACTOR XIII LEVELS AFTER REPLACEMENT THERAPY IN SEVERE CONGENITAL FACTOR XIII DEFICIENCY: IS THERE A ROLE FOR FACTOR XIII UPTAKE BY MEGAKARYOCYTES?
    Radu, C. M.
    Bulato, C.
    Campello, E.
    Sartorello, F.
    Zanon, E.
    Milan, M.
    Gavasso, S.
    Spiezia, L.
    Simioni, P.
    HAEMATOLOGICA, 2016, 101 : 2 - 2
  • [5] Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency
    Cojutti, Pier Giorgio
    Zanon, Ezio
    Pasca, Samantha
    Pea, Federico
    CLINICAL PHARMACOKINETICS, 2022, 61 (04) : 505 - 513
  • [6] Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency
    Pier Giorgio Cojutti
    Ezio Zanon
    Samantha Pasca
    Federico Pea
    Clinical Pharmacokinetics, 2022, 61 : 505 - 513
  • [7] Comparison of patient experience (PE) and health-related quality of life (HRQoL) in people with severe factor IX deficiency before and after an en-masse switch to an extended half-life (EHL) factor IX (FIX) concentrate
    Johnston, K.
    Singleton, E.
    Ryan, K.
    O'Connell, N.
    HAEMOPHILIA, 2019, 25 : 119 - 120
1